The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta-Analysis of Clinical Trials

Abstract

Major depression is a common, recurrent, and chronic disease that negatively affects the quality of life and increases the risk of mortality. Several studies have demonstrated that curcumin, the yellow-pigmented substance of the turmeric, possesses antidepressant properties. The aim of this review is to meta-analytically assess the antidepressant effect of curcumin in patients with major depressive disorders. We extensively searched the literature until August 2015. The random-effect model was used to calculate the pooled standardized difference of means (SMD). Subgroup analyses were also performed to examine the effect of different study characteristics on the overall model. Six clinical trials met the inclusion criteria. Overall, curcumin administration showed a significantly higher reduction in depression symptoms [SMD = -0.34; 95% confidence interval (CI) = -0.56, -0.13; p = 0.002]. Subgroup analyses showed that curcumin had the highest effect when given to middle-aged patients (SMD = -0.36; 95% CI = -0.59; -0.13; p = 0.002), for longer duration of administration (SMD = -0.40; 95% CI = -0.64, -0.16; p = 0.001), and at higher doses (SMD = -0.36; 95% CI = -0.59, -0.13; p = 0.002). The administration of new formulation of curcumin (BCM-95) had non-significantly higher effect on depression as compared with the conventional curcumin-piperine formula. We conclude that there is supporting evidence that curcumin administration reduces depressive symptoms in patients with major depression.

Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets

“…Meta-analysis of clinical trials demonstrated that adjunctive treatment with curcumin might be beneficial in terms of improvement in depressive symptoms in patients with MDD, especially in middle-age patients with longer duration of administration and at higher doses (Al-Karawi et al, 2016). More recently, effects of curcumin at different doses (250 mg b.i.d.…”

An investigation of the effects of curcumin on iron overload, hepcidin level, and liver function in β‐thalassemia major patients: A double‐blind randomized controlled clinical trial

“…Preclinical and clinical evidences demonstrated that curcumin has a strong potential to protect against oxidative stress, inflammation, cancer, and metabolic and neurological diseases (Kunnumakkara et al, , Al‐Karawi, Al Mamoori, & Tayyar, , Daily, Yang, & Park, , Sahebkar & Henrotin, , Nasseri et al, ). In the present study, it was observed that curcumin supplementation significantly reduced serum NTBI, an index of free iron, in these patients.…”

Targeting Epigenetics Signaling with Curcumin: A Transformative Drug Lead in Treatment of Schizophrenia?

“…Sign Path Pharm PA USA has prioritized cancer treatment for Lipocurc in the research and development (R/D) platform; however, we consider it worthwhile to repurpose Lipocurc for likely therapeutic effects in schizophrenia. A recent RCT study found infusion of nitroprusside in modulating NMDA receptor, significantly improved the positive, negative, depressive and anxiety symptoms: the changes in Brief Psychiatric Rating scale: BPRS scores persisted for 4 weeks post-infusion [72]. No adverse events were reported.…”